An amorphous solid dispersion is a formulation strategy that disperses a drug within a polymer matrix to improve dissolution and enhance oral bioavailability for poorly soluble compounds.

ASD technologies are commonly used for BCS Class II and Class IV compounds where low aqueous solubility limits oral absorption and systemic exposure.

Initial characterization studies can often be performed using as little as 1–10 mg of API, while formulation screening typically requires only small quantities of material.

Computational modeling helps identify promising drug-polymer combinations before laboratory testing, improving efficiency and reducing material requirements.

ASD screening identifies promising formulations through computational, in vitro, and PK evaluation. Stability studies assess the physical and chemical stability of those formulations over time to support development and manufacturing decisions.

Yes. Following formulation optimization, BioDuro supports process development, scale-up, engineering batches, clinical manufacturing, packaging, labeling, and clinical supply.

Depending on program requirements, optimized formulations can be prepared for IND-enabling development in approximately 8–12 weeks.